Q-omics provides the consensus-scored FBXO22 profile across patient tissues and cancer cell-line models. FBXO22 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FBXO22 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, FBXO22 RNA expression shows 20,397 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where FBXO22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO22 survival associations across molecular data types. FBXO22 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO22 RNA expression–survival associations across cancer types. High FBXO22 expression shows unfavorable associations in UVM, PAAD, LGG and LUAD, but favorable associations in UCEC and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for FBXO22 RNA expression.
This table summarizes FBXO22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO22 shows higher tumor expression in BLCA, COAD, HNSC, LUAD, LIHC and STAD. The BLCA box plot shows higher FBXO22 RNA expression in tumor versus normal tissue (log2 FC = +0.942, t-test p < 0.001).
This table shows molecular features associated with FBXO22 in patient tissues and cancer cell lines. In patient samples, FBXO22 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
